| Literature DB >> 12387744 |
Nobuhiko Kayagaki1, Minhong Yan, Dhaya Seshasayee, Hua Wang, Wyne Lee, Dorothy M French, Iqbal S Grewal, Andrea G Cochran, Nathaniel C Gordon, JianPing Yin, Melissa A Starovasnik, Vishva M Dixit.
Abstract
The TNF-like ligand BAFF/BLyS is a potent survival factor for B cells. It binds three receptors: TACI, BCMA, and BR3. We show that BR3 signaling promotes processing of the transcription factor NF-kappaB2/p100 to p52. NF-kappaB2/p100 cleavage was abrogated in B cells from A/WySnJ mice possessing a mutant BR3 gene, but not in TACI or BCMA null B cells. Furthermore, wild-type mice injected with BAFF-neutralizing BR3-Fc protein showed reduced basal NF-kappaB2 activation. BR3-Fc treatment of NZB/WF1 mice, which develop a fatal lupus-like syndrome, inhibited NF-kappaB2 processing and attenuated the disease process. Since inhibiting the BR3-BAFF interaction has therapeutic ramifications, the ligand binding interface of BR3 was investigated and found to reside within a 26 residue core domain. When stabilized within a structured beta-hairpin peptide, six of these residues were sufficient to confer binding to BAFF.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12387744 DOI: 10.1016/s1074-7613(02)00425-9
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745